RxDoctor Payments DataLook up a doctor →

William Justiz, MD

Neurology · Naples, FLNPI 1275583916

Payments from drug & device makers

$6,060,780in general payments, 2019–2025

Across 918 payments — averaging $6602.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$1.4M
  • Eli Lilly$1.3M
  • Genentech, Inc.$1.2M
  • UCB SA$793K
  • E.r. Squibb & Sons, L.L.C.$400K
  • Alnylam Pharmaceuticals Inc.$341K
  • plus $595K from 42 others
$37,109in research payments, 2019–2025

Across 6 payments — averaging $6184.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$37K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC82$1,442,815
Eli Lilly21$1,268,750
Genentech, Inc.229$1,220,518
UCB SA12$792,792
E.r. Squibb & Sons, L.L.C.11$400,331
Alnylam Pharmaceuticals Inc.148$340,911
Sage Therapeutics, LLC12$313,275
Novo Nordisk AS46$121,548
Regeneron30$60,624
Acadia Pharmaceuticals Inc32$43,248
Avanir Pharmaceuticals, Inc.13$40,747
Merck29$5,967
Otsuka Pharmaceutical Development & Commercialization, Inc.1$4,000
Novartis61$1,081
AbbVie(2 entities)57$892
Eisai Inc.16$513
UCB, Inc.15$452
Lilly USA, LLC15$286
Amgen(2 entities)12$249
Biogen6$219
Lundbeck LLC6$192
GE HealthCare7$141
Genentech USA, Inc.3$131
Bristol Myers Squibb6$125
EMD Serono, Inc.6$121
Johnson & Johnson5$76
Teva Pharmaceuticals USA, Inc.6$74
Otsuka America Pharmaceutical, Inc.3$67
Acorda Therapeutics, Inc2$49
AstraZeneca2$47
Averitas Pharma Inc.1$46
Sunovion Pharmaceuticals Inc.3$46
Avion Pharmaceuticals2$41
Sanofi1$40
Novo Nordisk1$36
Boston Scientific2$36
Medtronic(2 entities)2$36
Greenwich Biosciences, Inc.1$33
Octapharma USA, Inc.2$32
Banner Life Sciences, LLC1$25
Mallinckrodt Hospital Products Inc.1$24
Abbott1$24
Argenx US, Inc.1$23
Grifols USA, LLC1$23
Aprecia Pharmaceuticals, LLC1$21
MDD US Operations, LLC1$20
Axsome Therapeutics, Inc.1$19
Tanabe Pharma America, Inc.1$13

How this compares

$6,060,780 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$315,160
Medicare patients
864
Services billed
2,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Naples

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →